Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer’s disease

References

• Pákáski M, Kálmán J. (2008). Interactions between the amyloid and cholinergic mechanisms in Alzheimer’s disease. Neurochem Int, 53:103–111.
   PubMed Web of Science ®Google Scholar
• Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. (2001). Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Neurosci Lett, 300:157–160.
   PubMed Web of Science ®Google Scholar
• Mangialasche F, Polidori MC, Monastero R, Ercolani S, Camarda C, Cecchetti R et al. (2009). Biomarkers of oxidative and nitrosative damage in Alzheimer’s disease and mild cognitive impairment. Ageing Res Rev, 8:285–305.
   PubMed Web of Science ®Google Scholar
• Feng Z, Qin C, Chang Y, Zhang JT. (2006). Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer’s disease. Free Radic Biol Med, 40:101–109.
   PubMed Web of Science ®Google Scholar
• Lu J, Zheng YL, Wu DM, Luo L, Sun DX, Shan Q. (2007). Ursolic acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. Biochem Pharmacol, 74:1078–1090.
   PubMed Web of Science ®Google Scholar
• Youdim MB, Buccafusco JJ. (2005). CNS Targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases. J Neural Transm, 112:519–537.
   PubMed Web of Science ®Google Scholar
• Jiang H, Luo X, Bai D. (2003). Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: A drug of traditional chinese medicine origin for the treatment of Alzheimer’s disease. Curr Med Chem, 10:2231–2252.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X et al. (2008). Potential therapeutic targets of huperzine A for Alzheimer’s disease and vascular dementia. Chem Biol Interact, 175:396–402.
   PubMed Web of Science ®Google Scholar
• Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. (2009). Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: An updated meta-analysis. J Neural Transm, 116:457–465.
   PubMed Web of Science ®Google Scholar
• Wang R, Yan H, Tang XC. (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin, 27:1–26.
   PubMed Web of Science ®Google Scholar
• Xu H, Shi DZ. (2003). The clinical applications and pharmacologic effects of ligustrazine. Chin J Integr Tradit West Med, 23:376–377.
   Google Scholar
• Cheng XR, Zhang L, Hu JJ, Sun L, Du GH. (2007). Neuroprotective effects of tetramethylpyrazine on hydrogen peroxide-induced apoptosis in PC12 cells. Cell Biol Int, 31:438–443.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wei MJ, He M, Jin WB, Zhao HS, Yao WF. (2008). The effects of tetramethylpyrazine on learning and memory abilities of mice with Alzheimer disease and its possible mechanism. Chin Pharmacol Bull, 24:1088–1092.
   Google Scholar
• Qi X, Ackermann C, Sun D, Liu R, Sheng M, Hou H. (2002). The prediction of plasma and brain levels of 2,3,5,6-tetramethylpyrazine following transdermal application. AAPS Pharmsci, 4:1–8.
   Google Scholar
• Qian BC, Wang M, Zhou ZF, Chen K, Zhou RR, Chen GS. (1995). Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol Sin, 16, 396–398.
   PubMed Web of Science ®Google Scholar
• Subedi RK, Oh SY, Chun MK, Choi HK. (2010). Recent advances in transdermal drug delivery. Arch Pharm Res, 33:339–351.
   PubMed Web of Science ®Google Scholar
• Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S. (2009). Microemulsions as a surrogate carrier for dermal drug delivery. Drug Dev Ind Pharm, 35:525–547.
   PubMed Web of Science ®Google Scholar
• El-Hadidy GN, Ibrahim HK, Mohamed MI, El-Milligi MF. (2011). Microemulsions as vehicles for topical administration of voriconazole: Formulation and in vitro evaluation. Drug Dev Ind Pharm. DOI: 10.3109/03639045.2011.590731.
   PubMed Web of Science ®Google Scholar
• Padula C, Nicoli S, Santi P. (2009). Innovative formulations for the delivery of levothyroxine to the skin. Int J Pharm, 372:12–16.
   PubMed Web of Science ®Google Scholar
• Shi J, Liu Q, Wang Y, Luo G. (2010). Coadministration of huperzine A and ligustrazine phosphate effectively reverses scopolamine-induced amnesia in rats. Pharmacol Biochem Behav, 96:449–453.
   PubMed Web of Science ®Google Scholar
• Zhao X, Liu JP, Zhang X, Li Y. (2006). Enhancement of transdermal delivery of theophylline using microemulsion vehicle. Int J Pharm, 327:58–64.
   PubMed Web of Science ®Google Scholar
• Chandra A, Sharma PK, Irchhiaya R. (2009). Microemulsion-based hydrogel formulation for transdermal delivery of dexamethasone. Asian J Pharm, 1:30–36.
   Google Scholar
• Huang YB, Lin YH, Lu TM, Wang RJ, Tsai YH, Wu PC. (2008). Transdermal delivery of capsaicin derivative-sodium nonivamide acetate using microemulsions as vehicles. Int J Pharm, 349:206–211.
   PubMed Web of Science ®Google Scholar
• Williams AC, Barry BW. (2004). Penetration enhancers. Adv Drug Deliv Rev, 56:603–618.
   PubMed Web of Science ®Google Scholar
• Elias PM, Tsai J, Menon GK, Holleran WM, Feingold KR. (2002). The potential of metabolic interventions to enhance transdermal drug delivery. J Investig Dermatol Symp Proc, 7:79–85.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. (2011). Role of novel terpenes in transcutaneous permeation of valsartan: Effectiveness and mechanism of action. Drug Dev Ind Pharm, 37:583–596.
   PubMed Web of Science ®Google Scholar
• Heard CM, Kung D, Thomas CP. (2006). Skin penetration enhancement of mefenamic acid by ethanol and 1,8-cineole can be explained by the ‘pull’ effect. Int J Pharm, 321:167–170.
   PubMed Web of Science ®Google Scholar
• Chadha G, Sathigari S, Parsons DL, Jayachandra Babu R. (2011). In vitro percutaneous absorption of genistein from topical gels through human skin. Drug Dev Ind Pharm, 37:498–505.
   PubMed Web of Science ®Google Scholar
• Zhang CF, Yang ZL, Luo JB, Zhu QH, Zhao HN. (2007). Effects of cinnamene enhancers on transdermal delivery of ligustrazine hydrochloride. Eur J Pharm Biopharm, 67:413–419.
   PubMed Web of Science ®Google Scholar
• Zhao JH, Fu JH, Wang SM, Su CH, Shan Y, Kong SJ et al. (2007). A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: In vitro and in vivo characterization. Int J Pharm, 337:88–101.
   PubMed Web of Science ®Google Scholar
• Ye JC, Zeng S, Zheng GL, Chen GS. (2008). Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm, 356:187–192.
   PubMed Web of Science ®Google Scholar
• Shen T, Xu H, Weng W, Zhang J. (2006, Nov 9). Study on the human pharmacokinetics and relative bioavailability of tetramethylpyrazine phosphate patch. Proceedings of the Sixth Chinese Pharmaceutical Association Annual Meeting, Guangzhou, China.
   Google Scholar
• Huang JH, Huang XH, Chen ZY, Zheng QS, Sun RY. (2004). Dose conversion among different animals and healthy volunteers in pharmacological study. Chin J Chin Pharmacol Ther, 9:1069–1072.
   Google Scholar
• Oh JH, Choi BJ, Chang MS, Park SK. (2009). Nelumbo nucifera semen extract improves memory in rats with scopolamine-induced amnesia through the induction of choline acetyltransferase expression. Neurosci Lett, 461:41–44.
   PubMed Web of Science ®Google Scholar